Garo Garibian
Cardiovascular Disease · Philadelphia, PANPI 1215909247
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,450 of the $114,958 with a category attached, or 81.3%. 30 manufacturers reported payments, led by Johnson & Johnson at 41.2% of the total. Reporting peaked in 2019 at $29,744 and has fallen 66.9% since, to $9,850 in 2023. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $246.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$47K
- Esperion Therapeutics, Inc.$22K
- AstraZeneca$21K
- Boston Scientific$16K
- Impulse Dynamics (USA) Inc.$2K
- Amgen$1K
- plus $6K from 24 others
What the payments were for
- Consulting fees$6331%
- Speaking & faculty fees$93,45081%
- Travel & lodging$4,5004%
- Food & beverage$16,35714%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $47,362 |
| Esperion Therapeutics, Inc. | 22 | $21,855 |
| AstraZeneca | 59 | $20,792 |
| Boston Scientific | 69 | $15,970 |
| Impulse Dynamics (USA) Inc. | 25 | $1,582 |
| Amgen | 30 | $1,406 |
| E.r. Squibb & Sons, L.L.C. | 20 | $928 |
| Novartis | 56 | $764 |
| Daiichi Sankyo Inc. | 15 | $749 |
| Amarin Pharma, Inc. | 6 | $614 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $369 |
| Medtronic(2 entities) | 3 | $362 |
| W. L. Gore & Associates, Inc. | 1 | $350 |
| Boehringer Ingelheim | 13 | $331 |
| Merck | 10 | $243 |
| Pfizer | 14 | $201 |
| Akcea Therapeutics, Inc. | 3 | $165 |
| Sanofi-aventis U.S. LLC | 7 | $145 |
| Bayer | 7 | $144 |
| Abbott | 2 | $143 |
| Lundbeck LLC | 2 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| Althera Pharmaceuticals LLC | 2 | $44 |
| Biosense Webster, Inc. | 2 | $43 |
| Novo Nordisk | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Preventice Services, LLC | 1 | $20 |
| Medicomp Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$46,729
- NEXLETOL$21,555
- NEXLIZET$21,405
- FARXIGA$19,842
- Watchman$11,555
- WATCHMAN Access System$1,972
- OPTIMIZER$1,394
- Repatha$836
- GENERAL - THERAPIES$719
- Vascepa$610
- CAMZYOS$479
- INJECTAFER$367
- Product in Development$350
- OPTIMIZER SMART SYSTEM$148
- TEGSEDI$123
- ENTRESTO$122
- HeartMate$119
- INVOKANA$119
- JARDIANCE$116
- NORTHERA$109
How this compares
$114,958 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $17,215 |
| XareltoRivaroxaban | 16 | $12,658 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $834 |
| Metoprolol Succinate | 31 | $602 |
| Amlodipine Besylate | 28 | $258 |
| Atorvastatin Calcium | 11 | $195 |
| Rosuvastatin Calcium | 15 | $180 |
| Losartan Potassium | 16 | $174 |
| Metoprolol Tartrate | 24 | $165 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $136 |
| Furosemide | 16 | $64 |
| Azithromycin | 13 | $54 |
| Hydrochlorothiazide | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $201 | $17,21528 claims |
| Johnson & JohnsonXarelto | $47,362 | $12,65816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Norman FeinsmithPhiladelphia$94K
- Brian DrachmanPhiladelphia$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.